DSS, Inc. reported a revenue increase of 9% for the fiscal year ended December 31, 2025, totaling approximately $20.8 million, compared to $19.1 million in 2024. The growth was primarily driven by a 12% rise in printed product sales within the Product Packaging segment, which generated $18.1 million in revenue. However, the company experienced a significant decline in its Commercial Lending segment, with revenue dropping 80% to $45,000, attributed to several loans going into non-accrual status. The Biotechnology segment contributed $38,000 in revenue, marking its first reported income, while the Securities and Investment Management segment generated $2.5 million, down from $2.8 million in the previous year.
DSS's total costs and expenses decreased by 43% to $35.2 million, largely due to the absence of significant impairment charges that had impacted the previous year’s results. The company reported an operating loss of $14.4 million, an improvement from the $42.6 million loss in 2024. The net loss attributable to common stockholders was $23.9 million, compared to $46.9 million in the prior year. The company’s cash position also declined, with cash and cash equivalents at approximately $6.2 million as of December 31, 2025, down from $11.4 million a year earlier.
Strategically, DSS has focused on optimizing operational efficiencies and realigning resources across its business lines. The company sold its Plano, Texas facility for $9.5 million, using part of the proceeds to reduce outstanding debt. Additionally, DSS's subsidiary, Impact BioMedical, Inc., announced a merger agreement with Dr. Ashleys Limited, which is expected to create a combined public entity. The company also received FINRA approval for its subsidiary, Sentinel Brokers Company, to act as an underwriter for corporate securities offerings, enhancing its capabilities in the securities market.
Operationally, DSS reported a total employee headcount of 102 as of December 31, 2025. The company continues to face challenges, including a significant reliance on a single customer, which accounted for approximately 29% of its consolidated revenue. The company is also navigating a complex landscape of credit risks, with a loan loss reserve of approximately $7.5 million established to address potential defaults. Looking ahead, DSS aims to enhance its operational efficiency and explore new market opportunities while maintaining a disciplined approach to cost management and capital allocation.
About DSS, INC.
DSS, Inc. operates across diverse sectors including product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing. It develops innovative healthcare technologies, provides custom packaging solutions, offers financial services, and manages real estate investments. The company leverages strategic partnerships, patents, and a decentralized growth model to create long-term shareholder value through innovation, operational efficiency, and targeted market expansion.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.